Brought to you by 
GSK to develop and market Fabre-Kramer's antidepressants
02 Mar 2007
Executive Summary
Continuing its recent streak of in-licensing near-term drug candidates, GlaxoSmithKline has gotten exclusive global rights to develop and sell Fabre-Kramer Pharmaceuticals' (specialty CNS pharma) Phase III gepirone ER plus follow-on molecules.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK to develop and market Fabre-Kramer's antidepressants
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice